Semagacestat Is a Pseudo-Inhibitor of γ-Secretase

Semagacestat Is a Pseudo-Inhibitor of γ-Secretase

γ-secretase inhibitors (GSI) are drugs developed to decrease amyloid-β peptide (Aβ) production by inhibiting intramembranous cleavage of β-amyloid protein precursor (βAPP). However, a large phase 3 trial of semagacestat, a potential non-transition state analog (non-TSA) GSI, in patients with Alzheim...

Full description

Bibliographic Details
Main Authors: Shinji Tagami, Kanta Yanagida, Takashi S. Kodama, Mako Takami, Naoki Mizuta, Hiroshi Oyama, Kouhei Nishitomi, Yu-wen Chiu, Toru Okamoto, Takeshi Ikeuchi, Gaku Sakaguchi, Takashi Kudo, Yoshiharu Matsuura, Akio Fukumori, Masatoshi Takeda, Yasuo Ihara, Masayasu Okochi
Format: Article
Language:English
Published: Elsevier 2017-10-01
Series:Cell Reports
Subjects:
Alzheimer’s disease
γ-secretase inhibitors
clinical trials
semagacestat
Aβ hypothesis
γ-byproducts
RO4929097
MK-0752
avagacetat
anti-cancer drugs
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124717313074

Internet

http://www.sciencedirect.com/science/article/pii/S2211124717313074

Similar Items